Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.

MLA

Shim, Seung Cheol, et al. “Efficacy and Safety of Switching from Rituximab to Biosimilar CT-P10 in Rheumatoid Arthritis: 72-Week Data from a Randomized Phase 3 Trial.” Rheumatology (Oxford, England), vol. 58, no. 12, Dec. 2019, pp. 2193–202. EBSCOhost, https://doi.org/10.1093/rheumatology/kez152.

APA

Shim, S. C., Božić-Majstorović, L., Berrocal Kasay, A., El-Khouri, E. C., Irazoque-Palazuelos, F., Cons Molina, F. F., Medina-Rodriguez, F. G., Miranda, P., Shesternya, P., Chavez-Corrales, J., Wiland, P., Jeka, S., Garmish, O., Hrycaj, P., Fomina, N., Park, W., Suh, C.-H., Lee, S. J., Lee, S. Y., … Yoo, D. H. (2019). Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial. Rheumatology (Oxford, England), 58(12), 2193–2202. https://doi.org/10.1093/rheumatology/kez152

Chicago

Shim, Seung Cheol, Ljubinka Božić-Majstorović, Alfredo Berrocal Kasay, Elias Chalouhi El-Khouri, Fedra Irazoque-Palazuelos, Francisco Fidencio Cons Molina, Francisco G Medina-Rodriguez, et al. 2019. “Efficacy and Safety of Switching from Rituximab to Biosimilar CT-P10 in Rheumatoid Arthritis: 72-Week Data from a Randomized Phase 3 Trial.” Rheumatology (Oxford, England) 58 (12): 2193–2202. doi:10.1093/rheumatology/kez152.